Results 101 to 110 of about 323,772 (303)
Introduction: Rural living Veterans with chronic kidney disease (CKD) and refractory hypertension (rHTN) have a higher mortality rate and are hospitalized more frequently than Veterans living in urban or suburban areas. They also face particularly unique
Kroll-Desrosiers, Aimee +5 more
core +1 more source
Wei Liang,1,2 Hua Zhang,2 Yi Wu,3 Zhiwei Lai,2 Weiqiang Zhang,3 Yuhao Cao,4 Lishan Tan,2 Zibo Xiong,2 Guang Yang,2 Zuying Xiong1,2 1Department of Nephrology, School of Clinical Medicine, Peking University Shenzhen Hospital, Anhui Medical University ...
Liang W +9 more
doaj
Objective The hematopoietic system maintains homeostasis by balancing myeloid and lymphoid cell production in the bone marrow (BM). In response to increased hematopoietic demand, extramedullary hematopoiesis (EMH) may occur in nonlymphoid organs. We investigated the role of EMH and kidney‐resident hematopoietic stem and progenitor cells (HSPCs) in ...
Hansol Yi +9 more
wiley +1 more source
Teerawat Thanachayanont,1 Methee Chanpitakkul,1 Salyaveth Lekagul,1 Kriang Tungsanga1,2 1Department of Nephrology, Bhumirajanagarindra Kidney Institute, Bangkok, Thailand; 2Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn ...
Thanachayanont T +3 more
doaj
IgG Glycosylation‐Dependent CLEC7A Signaling Drives Podocyte Dysfunction in Lupus Nephritis
Objective Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE) that can lead to end‐stage kidney disease and increased mortality. IgG from patients with LN displays abnormal glycosylation, contributing to podocyte injury.
Rohit Upadhyay +3 more
wiley +1 more source
Qingsong Chen, Gang Wang, Ruo Zhao, Qiyuan Hu, Jiayun Li, Yuting Wang, Jingyang Ran, Qi Huang, Guiquan Yu, Yanjia Luo, Xiaohui Liao Department of Nephrology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of ...
Chen Q +10 more
doaj
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease +20 more
wiley +1 more source
Feng M, Luo F, Wu H, et al. Drug Des Devel Ther. 2023;17:3169—3192. https://doi.org/10.2147/DDDT.S420135 We, the Editor and Publisher of Drug Design, Development and Therapy, have retracted the published article.
Feng M +7 more
doaj

